Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quizartinib vs placebo plus standard chemotherapy in newly diagnosed FLT3-ITD–positive AML
CTR20170661Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of quizartinib in acute myeloid leukemia (AML), sponsored by Daiichi Sankyo Co., Ltd.. Started Jun 2017; status: completed.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20170661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170661.